Literature DB >> 11167437

High-dose intrathecal diamorphine for analgesia after Caesarean section.

R Stacey1, R Jones, G Kar, A Poon.   

Abstract

Forty women undergoing elective Caesarean section under spinal anaesthesia using hyperbaric 0.5% bupivacaine were randomly allocated to receive either 0.5 mg or 1 mg intrathecal diamorphine. All women received diclofenac 100 mg at the end of surgery and morphine via a patient-controlled analgesia system. Oral analgesics were not used. Postoperative analgesia was more prolonged and more reliable in the 1-mg group. Mean time to first analgesia was 10.2 h in the 1-mg group and 6.9 h in the 0.5-mg group, and 45% in the 1-mg group used no morphine, compared with 10% in the 0.5-mg group. Mean morphine consumption over 24 h was 5.2 mg in the 1-mg group and 10.6 mg in the 0.5-mg group. Pain scores all tended to be lower in the 1-mg group but this was only significant at 4 h. There were no serious side-effects. Minor side-effects were common but well tolerated, and the incidence did not differ between the groups. If intrathecal diamorphine is used in combination with rectal diclofenac and without oral analgesia, then 1 mg provides superior analgesia to 0.5 mg without any worsening of the side-effects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11167437     DOI: 10.1046/j.1365-2044.2001.01763-3.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  2 in total

1.  The use of high-dose intrathecal diamorphine in laparoscopic bariatric surgery: a single-centre retrospective cohort study.

Authors:  Thomas G Wojcikiewicz; John Jeans; Anil Karmali; Jackline Nkhoma; Jonathan Cousins; Michael Kynoch
Journal:  Br J Pain       Date:  2018-09-19

2.  Intrathecal diamorphine for perioperative analgesia during colorectal surgery: a cross-sectional survey of current UK practice.

Authors:  Joseph Alderman; Amit Sharma; Jaimin Patel; Fang Gao-Smith; Ciro Morgese
Journal:  BMJ Open       Date:  2022-08-18       Impact factor: 3.006

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.